Lenalidomide Accord 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0023/G 
This was an application for a group of variations. 
16/05/2023 
23/06/2023 
SmPC, 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Labelling and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0020/G 
This was an application for a group of variations. 
30/11/2022 
n/a 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
Page 2/6 
 
 
 
 
 
 
 
 
 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
IAIN/0019 
B.II.b.1.a - Replacement or addition of a 
01/06/2022 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IA/0018 
A.7 - Administrative change - Deletion of 
07/01/2022 
30/01/2023 
Annex II and 
manufacturing sites 
PL 
IA/0017 
B.II.b.4.a - Change in the batch size (including batch 
23/09/2021 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
PSUSA/1838/
Periodic Safety Update EU Single assessment - 
22/07/2021 
16/09/2021 
Refer to Scientific conclusions and grounds recommending 
202012 
lenalidomide 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/1838/202012. 
IB/0016 
B.II.b.3.z - Change in the manufacturing process of 
03/08/2021 
n/a 
the finished or intermediate product - Other variation 
IB/0015 
C.I.11.z - Introduction of, or change(s) to, the 
10/05/2021 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IA/0014 
B.I.a.3.a - Change in batch size (including batch size 
09/04/2021 
n/a 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
Page 3/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0011/G 
This was an application for a group of variations. 
17/02/2021 
09/03/2021 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0012/G 
This was an application for a group of variations. 
16/02/2021 
09/03/2021 
SmPC, 
Labelling and 
PL 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
IB/0010/G 
This was an application for a group of variations. 
18/12/2020 
29/01/2021 
SmPC, Annex 
Page 4/6 
 
 
 
 
 
 
 
 
 
 
 
 
II and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
PSUSA/1838/
Periodic Safety Update EU Single assessment - 
23/07/2020 
24/09/2020 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
201912 
lenalidomide 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/1838/201912. 
IB/0008/G 
This was an application for a group of variations. 
09/09/2020 
22/10/2020 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 5/6 
 
 
 
 
 
 
 
 
 
 
IAIN/0009 
B.II.b.2.c.1 - Change to importer, batch release 
28/07/2020 
22/10/2020 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0004 
B.I.a.1.a - Change in the manufacturer of AS or of a 
13/03/2020 
n/a 
starting material/reagent/intermediate for AS - The 
proposed manufacturer is part of the same 
pharmaceutical group as the currently approved 
manufacturer 
IB/0005 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
20/02/2020 
27/03/2020 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
PSUSA/1838/
Periodic Safety Update EU Single assessment - 
05/09/2019 
n/a 
PRAC Recommendation - maintenance 
201812 
lenalidomide 
IAIN/0002 
B.II.b.2.c.1 - Change to importer, batch release 
08/03/2019 
27/03/2020 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
T/0001 
Transfer of Marketing Authorisation 
11/01/2019 
01/03/2019 
SmPC, 
Labelling and 
PL 
Page 6/6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
